$4.70
0.020.43%
Last update: 8:50 AM
15 minutes delayed
Acelyrin
SLRNNASDAQ
want to know what
the Bulls & Bears Say?
Acelyrin (NASDAQ:SLRN) Stock, Analyst Ratings, Price Targets, Forecasts
Acelyrin Inc has a consensus price target of $18.86 based on the ratings of 23 analysis. The 3 most-recent analyst ratings were released by Wells Fargo, HC Wainwright & Co., and HC Wainwright & Co. on July 8, 2024, May 22, 2024, and May 15, 2024, respectively. With an average price target of $15.67 between Wells Fargo, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 233.33% upside for Acelyrin Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
HC Wainwright & Co.
Citigroup
Morgan Stanley
Jefferies
1calculated from analyst ratings
Analyst Ratings for Acelyrin
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2024 | Buy Now | 176.6% | Wells Fargo | Derek Archila | $13 → $13 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | 282.98% | HC Wainwright & Co. | Emily Bodnar | $16 → $18 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | 240.43% | HC Wainwright & Co. | Emily Bodnar | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 282.98% | HC Wainwright & Co. | Emily Bodnar | $28 → $18 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 495.74% | HC Wainwright & Co. | Emily Bodnar | → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | Buy Now | 176.6% | Wells Fargo | Derek Archila | $11 → $13 | Maintains | Equal-Weight | Get Alert |
| 03/20/2024 | Buy Now | 538.3% | HC Wainwright & Co. | Emily Bodnar | → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 538.3% | HC Wainwright & Co. | Emily Bodnar | → $30 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2023 | Buy Now | 134.04% | Wells Fargo | Derek Archila | → $11 | Initiates | → Equal-Weight | Get Alert |
| 12/08/2023 | Buy Now | 70.21% | Citigroup | Samantha Semenkow | → $8 | Initiates | → Neutral | Get Alert |
| 11/29/2023 | Buy Now | 176.6% | Morgan Stanley | Vikram Purohit | $19 → $13 | Maintains | Equal-Weight | Get Alert |
| 11/28/2023 | Buy Now | 155.32% | Jefferies | Akash Tewari | $15 → $12 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 538.3% | HC Wainwright & Co. | Emily Bodnar | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 304.26% | Morgan Stanley | Vikram Purohit | $39 → $19 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 09/12/2023 | Buy Now | 538.3% | HC Wainwright & Co. | Emily Bodnar | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 729.79% | Morgan Stanley | Vikram Purohit | $29 → $39 | Maintains | Overweight | Get Alert |
| 09/05/2023 | Buy Now | 836.17% | HC Wainwright & Co. | Emily Bodnar | → $44 | Initiates | → Buy | Get Alert |
| 06/26/2023 | Buy Now | 517.02% | Morgan Stanley | Vikram Purohit | $29 → $29 | Maintains | Overweight | Get Alert |
| 06/21/2023 | Buy Now | 517.02% | Morgan Stanley | Vikram Purohit | → $29 | Reiterates | Overweight → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 517.02% | Morgan Stanley | Vikram Purohit | → $29 | Initiates | → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 559.57% | Jefferies | Akash Tewari | → $31 | Initiates | → Buy | Get Alert |
| 05/30/2023 | Buy Now | — | TD Cowen | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 05/30/2023 | Buy Now | 1346.81% | Piper Sandler | Yasmeen Rahimi | → $68 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Acelyrin (SLRN) stock?
The latest price target for Acelyrin (NASDAQ:SLRN) was reported by Wells Fargo on July 8, 2024. The analyst firm set a price target for $13.00 expecting SLRN to rise to within 12 months (a possible 176.60% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acelyrin (SLRN)?
The latest analyst rating for Acelyrin (NASDAQ:SLRN) was provided by Wells Fargo, and Acelyrin upgraded their overweight rating.
When was the last upgrade for Acelyrin (SLRN)?
The last upgrade for Acelyrin Inc happened on July 8, 2024 when Wells Fargo raised their price target to $13. Wells Fargo previously had an equal-weight for Acelyrin Inc.
When was the last downgrade for Acelyrin (SLRN)?
The last downgrade for Acelyrin Inc happened on September 13, 2023 when Morgan Stanley changed their price target from $39 to $19 for Acelyrin Inc.
When is the next analyst rating going to be posted or updated for Acelyrin (SLRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acelyrin, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acelyrin was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Acelyrin (SLRN) correct?
While ratings are subjective and will change, the latest Acelyrin (SLRN) rating was a upgraded with a price target of $13.00 to $13.00. The current price Acelyrin (SLRN) is trading at is $4.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.